Efficacy of modified atkins ketogenic diet in chronic cluster headache: An open-label, single-arm, clinical trial

Cherubino Di Lorenzo, Gianluca Coppola, Davide Di Lenola, Maurizio Evangelista, Giulio Sirianni, Paolo Rossi, Giorgio Di Lorenzo, Mariano Serrao, Francesco Pierelli

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Drug-resistant cluster headache (CH) is still an open clinical challenge. Recently, our group observed the clinical efficacy of a ketogenic diet (KD), usually adopted to treat drug-resistant epilepsies, on migraine. Aim: Here, we aim to detect the effect of KD in a group of drug-resistant chronic CH (CCH) patients. Materials and methods: Eighteen drug-resistant CCH patients underwent a 12-week KD (Modified Atkins Diet, MAD), and the clinical response was evaluated in terms of response (≥50% attack reduction). Results: Of the 18 CCH patients, 15 were considered responders to the diet (11 experienced a full resolution of headache, and 4 had a headache reduction of at least 50% in terms of mean monthly number of attacks during the diet). The mean monthly number of attacks for each patient at the baseline was 108.71 (SD = 81.71); at the end of the third month of diet, it was reduced to 31.44 (SD = 84.61). Conclusion: We observed for the first time that a 3-month ketogenesis ameliorates clinical features of CCH. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT03244735.

Original languageEnglish
Article number64
JournalFrontiers in Neurology
Volume9
Issue numberFEB
DOIs
Publication statusPublished - Feb 12 2018

Fingerprint

Ketogenic Diet
Carbohydrate-Restricted Diet
Cluster Headache
Clinical Trials
Diet
Headache
Pharmaceutical Preparations
Migraine Disorders

Keywords

  • Cluster headache
  • Drug resistance
  • Ketogenesis
  • Ketogenic diet
  • Ketone bodies
  • Modified Atkins diet

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Efficacy of modified atkins ketogenic diet in chronic cluster headache : An open-label, single-arm, clinical trial. / Di Lorenzo, Cherubino; Coppola, Gianluca; Di Lenola, Davide; Evangelista, Maurizio; Sirianni, Giulio; Rossi, Paolo; Di Lorenzo, Giorgio; Serrao, Mariano; Pierelli, Francesco.

In: Frontiers in Neurology, Vol. 9, No. FEB, 64, 12.02.2018.

Research output: Contribution to journalArticle

Di Lorenzo, Cherubino ; Coppola, Gianluca ; Di Lenola, Davide ; Evangelista, Maurizio ; Sirianni, Giulio ; Rossi, Paolo ; Di Lorenzo, Giorgio ; Serrao, Mariano ; Pierelli, Francesco. / Efficacy of modified atkins ketogenic diet in chronic cluster headache : An open-label, single-arm, clinical trial. In: Frontiers in Neurology. 2018 ; Vol. 9, No. FEB.
@article{ba6d9c6af8f14951b102927bd3e78245,
title = "Efficacy of modified atkins ketogenic diet in chronic cluster headache: An open-label, single-arm, clinical trial",
abstract = "Introduction: Drug-resistant cluster headache (CH) is still an open clinical challenge. Recently, our group observed the clinical efficacy of a ketogenic diet (KD), usually adopted to treat drug-resistant epilepsies, on migraine. Aim: Here, we aim to detect the effect of KD in a group of drug-resistant chronic CH (CCH) patients. Materials and methods: Eighteen drug-resistant CCH patients underwent a 12-week KD (Modified Atkins Diet, MAD), and the clinical response was evaluated in terms of response (≥50{\%} attack reduction). Results: Of the 18 CCH patients, 15 were considered responders to the diet (11 experienced a full resolution of headache, and 4 had a headache reduction of at least 50{\%} in terms of mean monthly number of attacks during the diet). The mean monthly number of attacks for each patient at the baseline was 108.71 (SD = 81.71); at the end of the third month of diet, it was reduced to 31.44 (SD = 84.61). Conclusion: We observed for the first time that a 3-month ketogenesis ameliorates clinical features of CCH. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT03244735.",
keywords = "Cluster headache, Drug resistance, Ketogenesis, Ketogenic diet, Ketone bodies, Modified Atkins diet",
author = "{Di Lorenzo}, Cherubino and Gianluca Coppola and {Di Lenola}, Davide and Maurizio Evangelista and Giulio Sirianni and Paolo Rossi and {Di Lorenzo}, Giorgio and Mariano Serrao and Francesco Pierelli",
year = "2018",
month = "2",
day = "12",
doi = "10.3389/fneur.2018.00064",
language = "English",
volume = "9",
journal = "Frontiers in Neurology",
issn = "1664-2295",
publisher = "Frontiers Research Foundation",
number = "FEB",

}

TY - JOUR

T1 - Efficacy of modified atkins ketogenic diet in chronic cluster headache

T2 - An open-label, single-arm, clinical trial

AU - Di Lorenzo, Cherubino

AU - Coppola, Gianluca

AU - Di Lenola, Davide

AU - Evangelista, Maurizio

AU - Sirianni, Giulio

AU - Rossi, Paolo

AU - Di Lorenzo, Giorgio

AU - Serrao, Mariano

AU - Pierelli, Francesco

PY - 2018/2/12

Y1 - 2018/2/12

N2 - Introduction: Drug-resistant cluster headache (CH) is still an open clinical challenge. Recently, our group observed the clinical efficacy of a ketogenic diet (KD), usually adopted to treat drug-resistant epilepsies, on migraine. Aim: Here, we aim to detect the effect of KD in a group of drug-resistant chronic CH (CCH) patients. Materials and methods: Eighteen drug-resistant CCH patients underwent a 12-week KD (Modified Atkins Diet, MAD), and the clinical response was evaluated in terms of response (≥50% attack reduction). Results: Of the 18 CCH patients, 15 were considered responders to the diet (11 experienced a full resolution of headache, and 4 had a headache reduction of at least 50% in terms of mean monthly number of attacks during the diet). The mean monthly number of attacks for each patient at the baseline was 108.71 (SD = 81.71); at the end of the third month of diet, it was reduced to 31.44 (SD = 84.61). Conclusion: We observed for the first time that a 3-month ketogenesis ameliorates clinical features of CCH. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT03244735.

AB - Introduction: Drug-resistant cluster headache (CH) is still an open clinical challenge. Recently, our group observed the clinical efficacy of a ketogenic diet (KD), usually adopted to treat drug-resistant epilepsies, on migraine. Aim: Here, we aim to detect the effect of KD in a group of drug-resistant chronic CH (CCH) patients. Materials and methods: Eighteen drug-resistant CCH patients underwent a 12-week KD (Modified Atkins Diet, MAD), and the clinical response was evaluated in terms of response (≥50% attack reduction). Results: Of the 18 CCH patients, 15 were considered responders to the diet (11 experienced a full resolution of headache, and 4 had a headache reduction of at least 50% in terms of mean monthly number of attacks during the diet). The mean monthly number of attacks for each patient at the baseline was 108.71 (SD = 81.71); at the end of the third month of diet, it was reduced to 31.44 (SD = 84.61). Conclusion: We observed for the first time that a 3-month ketogenesis ameliorates clinical features of CCH. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT03244735.

KW - Cluster headache

KW - Drug resistance

KW - Ketogenesis

KW - Ketogenic diet

KW - Ketone bodies

KW - Modified Atkins diet

UR - http://www.scopus.com/inward/record.url?scp=85041923773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041923773&partnerID=8YFLogxK

U2 - 10.3389/fneur.2018.00064

DO - 10.3389/fneur.2018.00064

M3 - Article

VL - 9

JO - Frontiers in Neurology

JF - Frontiers in Neurology

SN - 1664-2295

IS - FEB

M1 - 64

ER -